back to Meetings page
- IMMPACT-XV Slide Presentations
- 1. What is the FDA perspective on biomarkers, surrogate endpoints, and related measures in drug development and approval?
- Marc Walton, MD
- 2. An academic perspective on the role of biomarkers and surrogate endpoints in analgesic clinical trials and the development of improved analgesic treatments
- Justin McArthur, MD
- 3. Treatment benefit and outcome assessment
- Laurie Burke, RPh, MPH
- 4. What is the role of imaging in analgesic clinical trials and the development of improved analgesic treatments?
- Irene Tracey, PhD
- 5. What is the role of quantitative sensory testing (QST) in analgesic clinical trials and the development of improved analgesic treatments?
- Ralf Baron, MD
- 6. What is the role of punch skin biopsy in analgesic clinical trials and the development of improved analgesic treatments?
- Michael Polydefkis, MD